Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + infliximab
- Development stage
- Unknown
- Lead developer
- Janssen Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous, Intramuscular
01
Overview
A combination therapy consisting of methotrexate, an immunomodulator, and infliximab (Remicade), a chimeric monoclonal antibody targeting TNF-α. This combination is primarily used in rheumatoid arthritis where infliximab is specifically indicated for use with methotrexate. The combination may help reduce immunogenicity against infliximab and provide synergistic anti-inflammatory effects.
- Brand names
- RemicadeInflectraRenflexisIxifiAvsola
- Other names
- infliximab + methotrexate
02
Targets
DHFR (Dihydrofolate reductase)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on methotrexate + infliximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + infliximab.